Overview

Observational Study on Safety of Room Temperature Stable NovoSeven® in Patients With Haemophilia A or B

Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
This study is conducted in Europe and Asia. The aim of this observational study is to monitor antibody formation towards the room temperature stable formulation of NovoSeven® (activated recombinant human factor VII).
Details
Lead Sponsor:
Novo Nordisk A/S
Treatments:
Factor VIII